Spinal osteobiologics have evolved substantially in this century after the development of many product categories such as growth factors, allograft, and stem cells. The indications for the use of novel biologics within spine surgery are rapidly expanding as the mechanism of each is elucidated. While the knowledge base of bone morphogenetic protein increases with each subsequent year, the application of new nanotechnology and cell-based strategies are being reported. This review will discuss the most recent data in novel osteobiologics, and where we could use future study.
T
he arena of spinal biologics continues to evolve as new technologies become available and the population that suffers from spinal disorders grows. While mainstays of treatment for these spinal conditions have been established over the past 5 decades, recent literature suggests that alternative technologies are in demand. Iliac crest autograft is considered the gold standard choice for posterolateral lumbar spine fusion, however, it is rarely used in practice now because of surgeon and patient concerns of morbidity such as donor site pain, wound complications, and increased operative time. 1, 2 Furthermore, the recent increase in the use of local bone graft has created new demandsthe identification of a cost-effective biologics to "extend" the bony healing effects of autograft. 3 Similarly, epidural steroid injections have been widely used by spine practitioners to reduce radicular pain, but recent literature suggest that these choices may not be cost-effective nor efficacious. 4 Finally, polyetheretherketone (PEEK) has been the material of choice for interbody cages by ABBREVIATIONS: ACS, autologous conditioned serum; ACDF, anterior cervical discectomy and fusion; BIC, bone-implant-contact; BMA, bone marrow aspirate; BMP, Bone morphogenetic protein; FDA, Food and Drug Administration; HA, hydroxyapatite; ICBG, iliac crest bone graft; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; PEEK, polyetheretherketone; sTNFRII, soluble TNF-receptor II; TNF, tumor necrosis factor spine surgeons for over 10 years despite its poor potential for osseointegration into host bone.
Novel spinal biologics will allow for the improvement of fusion rates, pain reduction, and clinical outcomes. However, as history has demonstrated, there are trends of early adoption of promising technology without proper guidance and consideration for potential complications. Spine practitioners must be aware of the mechanisms of action, potential side effects, and expected outcomes from the use of these products. This focused review will discuss the recent literature pertaining to these treatment modalities for the spine patient.
INTERBODY CAGE DEVELOPMENTS
Cage fusion technology was first encountered in 1988 with the introduction of the stainless steel Bagby cage, a cylindrical, fenestrated spacer used initially on horses, then modified for use in the human lumbar and cervical spine. 5 Since its inception, 3 materials have become the most commonly used including PEEK, titanium (Ti), and carbon fiber-reinforced polymers. While PEEK cages provide excellent biomechanical support, achievement of fusion has traditionally depended upon the addition of other osteoconductive or osteoinductive agents. Recently, advancements have focused on developments in material and surface processing with the primary goal of improving fusion rates by favorably impacting the host biological response.
Polyetheretherketone
PEEK is a synthetic, semicrystalline, thermoplastic polymer that is highly wear resistant, stable at high temperatures and during sterilization, and resistant to destruction by most substances. 6 First developed in 1978, the material was introduced for interbody cage production in the 1990s. Advantages of PEEK over Ti as they apply to interbody cage technology include its lower modulus of elasticity to avoid stress shielding, as well as radiolucency that allows for easier assessment of osseointegration and successful fusion.
However, PEEK is a hydrophobic material to which cells have a limited ability to bond and on which cultured osteoblasts have been shown to differentiate to a lesser degree than when cultured on Ti. 7 As a result, PEEK cages have been shown to be surrounded by thin layers of fibrous tissue rather than going on to direct integration with host bone 8 -a finding that may precipitate ongoing micromotion, nonunion, and symptom recurrence. In addition, a radiological phenomenon known as the PEEKhalo effect due to poor integration of host bone with PEEK has been recently described. 9 These suboptimal characteristics have led to the need to improve the bioactivity and osseointegration properties of these cages, while maintaining the radiolucency and biomechanical properties of PEEK. Devices have been created from composite materials of PEEK in combination with Ti, hydroxyapatite (HA), calcium silicate, bioglass, carbon fiber, or beta-tricalcium phosphate.
Ti-PEEK composite cages may be created by constructing Ti endplates around a PEEK core, compression molding, and coating via electron beam deposition or plasma spray coating, or direct metal laser sintering. In Vivo and preclinical studies of cell activity and osseointegration have demonstrated improved cell attachment, greater bone volume/tissue volume and increased bone deposition and remodeling, 10 improved cell survival and higher alkaline phosphatase activity, 11 less fibrous tissue encapsulation, more cortical bone adjacent to the implants and greater push-out strength, and greater osseointegration and pull-out strength. 12 While small case series demonstrate successful fusion and improved clinical outcomes with the use of these cages in anterior cervical discectomy and fusion (ACDF), 13 there have been concerns regarding the implant-surface material interface and how durable it may be. In Vitro studies of PEEK cages with Ti coating show a significant risk of the delamination during the insertion of the device.
14 This detrimental process could continue postoperatively as these cages continue to have micromotion after implantation.
Surface modifications using HA coating may be applied via plasma spray, cold spray, and aerosol deposition. In Vitro studies of the impact of HA coating on PEEK bioactivity have consistently demonstrated improved cell viability, adhesion, proliferation, and alkaline phosphatase activity. 15, 16 In Vitro implantation studies in rabbits have shown greater volume of periimplant bone formation, greater bone-implant-contact (BIC), and increased implant removal torque with greater BIC. 15, 17, 18 There have yet to be any published human clinical reports of HAcoated interbody implants in spine surgery.
Titanium
Used in orthopedic surgery since the 1940s because of its biocompatibility, low density, and high corrosion resistance, Ti has been used for interbody cages since 1980. Ti can also undergo subsequent modifications with heat, plasma spray, and electron beam melting that can improve cell adhesion and osseointegration. Conversely, this biomaterial has an increased elastic modulus (compared to PEEK and native host bone) predisposing the construct to stress shielding and potential subsidence. Furthermore, the use of metals traditionally makes confirmation of fusion on plain and advanced radiographic imaging difficult secondary to artifact. With its high mechanical strength, Ti can be produced in a porous form with porosity of 60% to 70%, pore sizes of 250 to 750 μm, and pore interconnectivity of greater than 99%. 19 Implants manufactured from porous Ti can also be chemically and thermally treated to render them bioactive. 20 These types of implants compare favorably to PEEK during biomechanical testing with push-out strength in preclinical studies. 21 Multiple surface modifications can be applied to Ti implants to improve both bone on-growth, the apposition of bone to the implant surface, and bone in-growth. These include heat or alkali treatment, porous material conversion, removal of sodium (Na) ions, and HA coating. The ability of cells to adhere to and proliferate on interbody cages can be influenced by surface roughness, which can be altered through mechanisms such as plasma spraying, electron beam melting, and 3-dimensional printing. Ti surfaces can also be modified through the addition of nanoparticles such as titanium oxide (TiO 2 ) and zirconia (ZrO 2 ). In Vitro studies demonstrate increased osteoblast differentiation and protein production associated with bone formation and decreased bone resorption with a microroughened compared to a smooth surface. 22 Preclinical studies have also shown that grit blasting, acid etching, and heat treatments to increase microroughness lead to higher BIC ratios with a greater effect from sequential treatments. 23 Adjusting the nanostructure of the surface of Ti implants can lead to even higher pull-out forces and BIC ratios than grit-blasted technology, 24 which can be synergistic with other treatments. 22 Although a clinical case series with bioactive Ti implants in transforaminal lumbar interbody fusion is available, 19 long-term comparative trials with these devices have not been published.
Alternative Materials
Tantalum (Ta; 73rd element on the periodic table) is a metal that has been used clinically in orthopedic surgery since the 1940s. Porous Ta is a metal with an open-cell structure resembling that of cancellous bone with an overall porosity of between 75% and 85%. It has one of the highest coefficients of friction of any orthopedic biomaterial, resulting in excellent primary stability of implants, and its low elastic modulus closely mimics that of subchondral bone. 25 Though direct bonding of Ta to bone is limited as it is relatively biologically inert, its openpore structure encourages bone remodeling, osseointegration, and vascularization. 26 Animal studies have demonstrated bone ingrowth of 8% to 15% into porous Ta implants at 12 weeks after implantation in goat and pig spines. 27, 28 In 2013, a Food and Drug Administration (FDA) Investigational Device Exemption study randomizing patients to singlelevel ACDF with a stand-alone porous Ta ring packed with autograft, porous Ta block, or iliac crest bone graft was terminated early secondary to a significantly lower fusion rate in the investigational groups at 24 months (44% vs 100%). 29 Concerns regarding lower fusion rates with the use of Ta have been expressed by other authors as well. 30, 31 While Ta implants have been reported in the setting of anterior, posterior, and transforaminal lumbar interbody fusion with high fusion rates, 32 these implants can lead to a higher rate of subsidence. 33 Furthermore, there are legitimate concerns with the excessive artifact on postoperative magnetic resonance imaging (MRI) and computed tomographic imaging after implantation. 34 Silicon nitride (Si 3 N 4 ) is a hydrophilic, negatively charged ceramic material with compression and strength properties superior to PEEK and Ti. 35 The surface charges can facilitate osseointegration by increasing adhesion of both cells and proteins in the area. 36 These implants can also decrease artifact on advanced imaging 37 and increase resistance to bacterial biofilm formation 38 compared to competing biomaterials. Industrysponsored randomized controlled trials comparing PEEK to silicon nitride in ACDF (CASCADE), 37 and transforaminal lumbar interbody fusion (SNAP), 35 are ongoing.
Bone Morphogenetic Protein-2
Bone morphogenetic proteins (BMPs) are soluble members of the transforming growth factor-β superfamily that are involved in the differentiation, maturation, and proliferation of mesenchymal stem cells (MSCs) into osteogenic cells. 2 They interact with serine-threonine kinase receptors present on the cell surface and transduce intracellular signals through the SMAD cascade, causing nuclear translocation and expression of target genes that influence osteogenesis. Since the United States (US) FDA approval of rhBMP-2 for single-level anterior lumbar interbody fusion with a specific Ti cage in 2002, its clinical use has seen dramatic variability depending on randomized controlled studies, case series, and expert opinion.
The growth of rhBMP-2 usage increased from 1116 cases in 2002 to 79 294 by 2011 with approximately 85% of it used in an off-label manner, 2,39 likely based upon multiple clinical studies that demonstrated superior or equivalent fusion rates as compared to iliac crest bone graft (ICBG). [40] [41] [42] After a series of postoperative adverse events attributable to rhBMP-2 were reported including prevertebral swelling, seroma/hematoma formation, radiculitis, osteolysis, heterotopic ossification, retrograde ejaculation, and increased rates of new malignancy, 2, [43] [44] [45] [46] clinical usage decreased. 47 Consequently, many authors have reported that rhBMP-2 was associated with risk of osteolysis, subsidence, increased reoperation rate, retrograde ejaculation, urinary retention, increased delayed infections, bone overgrowth, radiculitis, life-threatening complications when used in the anterior cervical spine, potential adverse effects to the central nervous system with rhBMP-2 exposure to the intradural space, early back and leg morbidity, and potential increased malignancy. 2, [43] [44] [45] [46] [48] [49] [50] These claims led to an independent review of industry-sponsored data by the University of York and Oregon Health and Science University dubbed "The Yale Open Data Access project." Three studies were published from this effort, concluding that while rhBMP-2 resulted in high fusion rates, there were no significant differences in outcomes when compared with those treated with ICBG. [51] [52] [53] Furthermore, there was an increased risk of complications when rhBMP-2 was used in the anterior cervical spine. Notably, the research groups' conclusions differed as it pertained to the associated risk of cancer from BMP-2.
After analyzing the data in an FDA Investigational Device Exemption study utilizing a high-dose formulation of rhBMP-2 (AMPLIFY) in patients with single-level degenerative lumbar disease, Carragee et al concluded that the incidence rate of a cancer per 100 person-years was 3.37 in the rhBMP-2 group compared to 0.050 in the control group (P = .0026). 43 However, since this publication, it has been pointed out that collective reporting of all cancers and its incidence may not be representative of the true effect on mutagenesis as there are inherent differences in cell behavior that are not considered. 46 To this end, the autocrine effects of rhBMP-2 on tumor growth are not fully understood. While some studies have shown that rhBMP-2/4 inhibits tumor cell growth in Vitro, 54, 55 its effect is critically dependent on the biological environment, inhibiting cell proliferation in the presence of androgen and stimulating growth in its absence. 56 A systematic review of available basic science literature did not find rhBMP-2 to cause cancer de novo. 57 Finally, multiple population-based studies have been published recently to increase our understanding of the complex interactions between exposure to BMP-2 and cancer. Kelly et al 58 retrospectively analyzed 467 916 Medicare patients who underwent spinal arthrodesis with 2.85-to 2.95-year follow-up. To address the limitations of addressing cancer risk collectively, Kelly et al 58 utilized the National Cancer Institute's Surveillance Epidemiology and End Results program to identify those tumors most commonly associated with clinical cancer risk. The data in this study suggested that rhBMP-2 appeared to be protective of cancer (ie, relative risk <1) in all but pancreatic tumors. It must be noted, however, rhBMP-2 dosage was not controlled for in their analysis. The absence of an association of BMP-2 and increased risk of cancer has been supported by other population-based studies as well. 48, 59 Subsequent clinical studies have failed to show increased risk of carcinogenicity even when high doses (average 115 mg) were employed 60 or when a large population of elderly US adults undergoing lumbar arthrodesis was reviewed.
NOVEL DESIGNS IN CARRIER TECHNOLOGY
Carriers for growth factors and cells should restrict factor movement, confine them to a location, and allow for a timedependent gradual release. Historically, autogenous bone graft, demineralized bone matrix, collagen, ceramics, and poly-L-lactic acid have all been used to deliver proteins into a biological environment, 62, 63 however, clinical performance is unpredictable. The scaffold material varies in its ability to resorb and remodel and many may have no binding affinity for rhBMP-2 resulting in a burst release right after implantation. 64 This can lead to supraphysiological dosages of rhBMP-2 clinically that can explain some of the reported complications such as seroma/hematoma formation and an exaggerated inflammatory response. 65, 66 Efforts to address these limitations have led to the development of hybrid biomaterials that integrate a conventional bioabsorbable collagen scaffold with supramolecular nanofibers designed to bind these growth factors. Lee et al 67 reported on the use of molecular building blocks known as peptide amphiphiles that can self-assemble into nanofibers of extracellular filaments. Similarly, a biomimetic scaffold displaying heparin sulfate to enhance rhBMP-2 retention demonstrates enhanced bone formation in rat models with femoral defects. 65 The use of nanoscale biomaterials greatly enhances the ability to provide molecular interactions between growth factors, cells, and synthetics. Consequently, the delivery of these nanofiber carriers can confine the endogenous levels of local growth factor as evidenced by a magnitude lower amount of rhBMP-2 requirement to achieve bony healing when compared to collagen sponge. 67 This bioactive scaffold system has the potential of achieving clinical benefits by reducing supraphysiologic doses of rhBMP-2.
By definition, biomimetics is the imitation of the models, systems, and elements of nature for the purpose of solving complex human problems. One example is P-15, which is a synthetic 15-amino acid peptide that mimics a part of collagen and has shown bone-healing efficacy. These types of molecules attempt to create a microenvironment that approximates the physiological processes in which bone is formed. In a prospective, randomized, single-blinded trial of single-level ACDF using P-15 vs local autograft, 89.0% vs 85.8% fusion rates were reported, respectively, at 1-year follow-up with equivalent clinical outcomes and complications. 68 Furthermore, in a single surgeon case series of 110 patients who underwent anterior lumbar interbody fusion using P-15 with a mean 24-month follow-up, fusion rates were reported to be 97.5%, 81%, and 100% for single-, double-, and triple-level surgery. 69 Although substantially more clinical study is needed to assess the ability of these types of peptides as a bone graft substitute, efficacy has been demonstrated in the interbody environment.
CELL-BASED TECHNOLOGIES
MSCs are self-renewing, pluripotent cells that have mutilineage potential and possess the ability to differentiate into osteoblasts in the correct context. 2 MSCs can be found in tissues such as bone marrow, muscle, periosteum, and adipose tissue. Rabbit and primate models utilizing MSCs isolated from bone marrow have demonstrated efficacy in spinal fusion. 70, 71 Bone marrow has varying amounts of MSCs depending on age and the presence or absence of metabolic diseases such as osteoporosis. Healthy adults have 1 MSC for every 50 000 nucleated cells. 2 Concentration techniques such as ex vivo expansion have also shown to be promising, although problems with sterility, culture time, and cost have limited its clinical applicability. For this reason, concentration and centrifugation of bone marrow aspirate has been useful in improving the yield of bone marrow derived-MSCs. Additionally, the location from which bone marrow is derived appears to have an impact on MSC concentration. Muschler et al 72, 73 demonstrated that vertebral pedicles have 71% greater osteogenic progenitor cell concentration than the iliac crest.
Gan et al 74 used autologous enriched MSCs derived from the iliac crest combined with a porous tricalcium phosphate scaffold for posterior spinal fusions with 95.1% of patients achieving fusion at final follow-up. Taghavi et al 75 conducted a retrospective cohort study analyzing 62 patients who underwent revision posterior lumbar fusion. Patients were divided into 3 cohorts: instrumented revision with rhBMP-2 on a collagen sponge, instrumented fusion with bone marrow aspirate (BMA) with demineralized bone matrix allograft (BMA), and instrumented fusion with autograft. While rhBMP-2 and BMA groups had equivalent 100% fusion rates in the single-level fusion subgroups, BMA only had a rate of 63.6% in multilevel fusions compared to a 100% fusion rate in the BMP and autograft cohorts. The authors recommended that BMA be considered in only singlelevel revision cases as a cost-protective measure.
There is a wide variation between the different allogeneic MSC-derived products available for clinical use with regard to their average donor age at harvest, total cellular concentration, percentage of MSCs, shelf life, and cell viability after defrosting. Because these bone graft products are traditionally regulated through the human cellular tissue product pathway, very little data proving efficacy are required before commercialization. As a result, although these products are safe for clinical use, its role in spinal fusion remains highly inconclusive. For example, in a nonindustry-sponsored matched cohort analysis of 1-and 2-level ACDF, McAnany et al 76 reported 87.7% fusion rate when Osteocel (NuVasive, San Diego, California) was used compared to 94.7% in the structural allograft control group (P = .19) at 1 year. More studies are needed to assess the cost-effectiveness of cellular-based strategies for spine care.
INJECTABLE BIOMATERIALS FOR RADICULOPATHY
The pathophysiology of disk-herniation radiculopathy is based on both mechanical compression 77 and biochemical irritation 78, 79 at the disk-nerve interface. The inflammatory basis of disk degenerative disease, further augmented with herniation, has been well established and recent work supports the involvement of autoimmune lymphocyte lineage activation. [80] [81] [82] While surgical discectomy in appropriately selected patients can provide for substantial improvements in pain, disability, and quality of life, 83 some patients may be managed by less invasive means for noncompressive but still irritative disease. 84 Current management strategies include rehabilitative physiotherapy, antiinflammatory and neuromodulator medications with judicious opioid use, and local drug application through either epidural or transforaminal delivery.
When epidural or perineural therapies are implemented, the most common agents currently include steroid with or without additional local anesthetic, hence potentially providing both diagnostic and therapeutic value. Leung and coworkers 85 have described a series of 232 lumbar radiculopathy patients among whom 80% experienced immediate response to therapy with the analgesic effect lasting for more than 12 weeks in 40% of patients. A systematic review by Manchikanti and coworkers 86 further reiterates that there is good evidence to support the transforaminal application of steroid with local anesthetic for the management of radiculitis secondary to disk herniation, and fair evidence when the underlying pathoanatomy is from spinal stenosis. However, despite its widespread and longstanding use, some studies suggest that these injections are cost-effective for the patient population as a whole. 4 More recently, a number of biomaterials have been examined for potentially improved management of diskherniation radiculopathy, with the goals of improving treatment efficacy by maximizing drug dose and compartmental longevity, while also limiting exposure to deleterious drug side effects.
Serum Products
Delivery of autologous conditioned serum (ACS) is a procedure by which patient's blood is extracted, modified, and locally reintroduced to the patient to primarily address inflammatory conditions. Essentially, this processing involves monocyte activation with the conditioned serum containing heightened levels of IL-1ra, IL-4, and IL-10. 87 This product has demonstrated efficacy in peripheral arthritic disease. 88, 89 Perineural delivery of ACS has been examined in a 2-group randomized controlled trial for patients with cervical disk-herniation radiculopathy, with epidural application of methylprednisolone or ACS. 90 Among 40 randomized patients with cervical radiculopathy, those receiving ACS experienced gradual and sustained improvement over the 6-month study period, whereas those receiving steroid experienced improvement with deterioration toward study completion. A separate trial for patients with lumbar disk-herniation radiculopathy demonstrates similar treatment effects of ACS to triamcinolone, with significant improvements among all patients for both pain and disability over the 6-month study period. 91 A more recent single-arm prospective observational study of ACS as a treatment option for lumbar radiculopathy was reported by Kumar and coworkers 92 who found clinically important improvements in pain, disability, and quality of life among a selected group of subacute painful radiculopathy patients of at least 6 weeks in duration without motor deficit, and in whom no epidural steroid injection had been performed in the 3 months prior to intervention and no opioid use was present in the 6 months prior to intervention.
TNF-α Inhibitors
Preclinical data by Allen and coworkers 93 suggest that value in local delivery of specific anticytokine therapy in experimental models of radiculopathy. Specifically, administration of a tumor necrosis factor (TNF)-α-binding protein, soluble TNF-receptor II (sTNFRII) that is the active component of etanercept, provided for improvement in rodent balance, gait, and mechanical sensitivity. Similarly, Onda and coworkers 94 have shown improvement of the histological dorsal root ganglion and supraspinal changes accompanying experimental disk-herniation radiculopathy. Further, Sinclair and coworkers 95 have also demonstrated that sTNFRII can attenuate the inflammatory phenotype exhibited by surgical human intervertebral disk tissue and hence potentially render the disk-nerve interface less irritative. Systemic administration of anti-TNF-α antibody for lumbar radiculopathy has been studied by Karpinnen and coworkers, 96 who compared outcomes of 10 patients who received a single intravenous infusion of antibody vs 62 patients who received a single periradicular saline infiltration (placebo group of a different randomized controlled trial). At 3-month follow-up, those patients who received systemic anti-TNF-α therapy exhibited more effective control of pain and more frequent return to work than the control group. A follow-up randomized controlled trial by the same group of 40 patients followed for 1 year revealed contradictory results, with no differences in pain, disability, quality of life, or eventual progression to surgical intervention. 97 The treatment arm also exhibited a 14% adverse event rate compared with none seen in the placebo arm.
Systemic delivery of anti-TNF-α compounds has the most clinical experience among patients with rheumatoid arthritis and Crohn's disease, and while successful for such systemic diseases, the array of toxicities owing to systemic exposure remain quite significant and need not be borne by patients with local inflammatory disease. 98 Kim and coworkers 99 have demonstrated in preclinical models that epidural TNF-α blockade did reverse both perineurial edema and Wallerian degeneration in a chronic compression model of rodent dorsal root ganglion injury. Perineural delivery of etanercept has been examined in a 3-group randomized controlled trial for adults with lumbar diskherniation radiculopathy, with epidural application of steroid, etanercept, or saline. 100 Among 84 randomized patients with subacute radiculopathy of fewer than 6 months, with a primary outcome of leg pain 1 month after injection, there was no advantage in the etanercept group for pain or disability when compared with the other treatments. A stated limitation of this work, however, is the potential underdosing of etanercept that was applied at 4 mg, with the results contradicting previous studies that suggested benefit albeit with higher dose administration.
In a systematic review of these various studies, based on low-quality evidence, Pimental and coworkers 101 recommended continued study of anti-TNF-α in the experimental setting for their potential effects on lumbar radiculopathy, although they did not recommend this therapy now for current clinical practice.
There is moderate quality evidence to support that this therapy does not have a higher adverse event rate when being applied to treat either disk-herniation radiculopathy or discogenic low back pain. Among human patients with disk-herniation-associated radiculopathy, application of such immunosuppressive therapy neither impeded normal disk resorptive processes, nor altered the likelihood of patients undergoing surgical intervention for treatment-refractory symptoms.
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Stem Cells
The predominant application of cell-based therapies for degenerative lumbar disk disease has largely focused on diskregenerative strategies. Pluripotent stem cells survive and increase proteoglycan matrix upon introduction to degenerative disk environment, [103] [104] [105] further enhanced with cell delivery in a 3-dimensional scaffold. Stabilization of the degenerating inflammatory milieu is important, with adipose-derived stem cells capable of chrondrogenic differentiation, 106 but exhibiting less matrix biosynthesis with inflammatory activation. 107 A pilot human study demonstrated the feasibility of delivering bone marrow-derived stem cells for degenerative disk disease, with improved back pain and disability correlated with disk height and hydration on MRI imaging. 108 Recently, Kulling and coworkers 109 demonstrated in rodent models that perineural application of juvenile human chondrocytes in a rat hemilaminectomy model did not lead to any durable behavioral or histological effects on the exposed neural tissue. There have hitherto been no clinical investigations defining the role of such therapy for patients with radicular pain phenotype.
CONCLUSION
Spinal biologics have many different applications to the human condition. While significant advances have been made in the development of bone graft substitutes in the past 3 decades, there still is no consensus on the type of bone graft that should be used for spine fusion. Similarly, recent data suggest that common techniques to treat patients of spinal disorders such as iliac crest bone graft and epidural steroid injections should be replacedbut by what? As we continue to see the rapid developments of novel spinal biologics, the answers to cost-effective, efficacious treatment modalities to this patient population will become clearer.
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